INVESTOR ALERT Levi & Korsinsky, LLP Announces Investigation Of NUPATHE INC. And Its Board Of Directors In Connection With The Sale Of The Company To Endo Health Solutions

Levi & Korsinsky notifies investors of NuPathe Inc. (“NuPathe”) (Nasdaq:PATH) of possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Endo Health Solutions (Nasdaq: ENDP).

Click here to learn more about the action http://zlk.9nl.com/nupathe-path/, or call: 877-363-5972. There is no cost or obligation to you.

Under the terms of the transaction, NuPathe shareholders will receive $2.85 for each share of NuPathe stock they own, as well as rights to receive additional payments up to $3.15 per share if NuPathe’s treatment ZECUITY reaches specified net sales over time. The transaction has a total approximate value of $105 million. The investigation concerns whether the NuPathe Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Endo Health Solutions is underpaying for NuPathe shares.

If you own NuPathe common stock and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/nupathe-path/.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010

If you liked this article you might like

Teva (TEVA) Acquires NuPathe (PATH) for $144 Million

NuPathe Picks Teva as Merger Partner

Why NuPathe Inc. (PATH) Is Up Today

Nupathe's Failure to Launch Leads to Modest Takeover

5 Stocks Under $10 Set to Soar